CSIRO, Australia’s national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern.
Published today in the peer-reviewed ACS Infectious Diseases journal, researchers showed the vaccine formulations triggered a strong immune response in mice, protected hamsters from the virus, and remained stable at 37°C up to a month and at 100°C for up to 90 minutes.
Most vaccines require refrigeration to remain effective, like Oxford-AstraZeneca which must be kept between 2-8°C and Pfizer which requires specialized cold storage at -70°C.
CSIRO scientists at the Australian Center for Disease Preparedness in Geelong contributed to the study by assessing vaccinated mice sera (blood samples) for efficacy against key coronavirus variants, including the Delta variant currently spreading globally including in Sydney.
Dr. S.S. Vasan, CSIRO’s COVID-19 project leader and co-author, said the Mynvax-vaccinated mice sera show a strong response to all variants of the live virus.
“Our data shows that all formulations of Mynvax tested result in antibodies capable of consistent and effective neutralization of the Alpha, Beta, Gamma and Delta SARS-CoV-2 variants of concern,” Dr. Vasan said.
CSIRO’s evaluation of the different Mynvax formulations will support selection of the most suitable candidate for planned human clinical trials in India later this year.
CSIRO’s Health and Biosecurity Director, Dr. Rob Grenfell, said the pandemic has demonstrated the need for global scientific collaboration to address the urgent demand for multiple cost-effective COVID-19 vaccines and treatments.
“CSIRO has a long history of developing and testing vaccines for humans and animals,” Dr. Grenfell said.
“Since the start of the pandemic, CSIRO has played a crucial role in fighting COVID-19 by conducting preclinical evaluation of two COVID-19 vaccines including Oxford-AstraZeneca, tracking emerging variants of concern, and monitoring wastewater to detect hotspots in the community.
“A thermostable or ‘warm vaccine‘ is critical for remote or resource-limited locations with extremely hot climates which lack reliable cold storage supply chains, including regional communities in Australia’s outback and the Indo-Pacific region.”
The peer-reviewed paper, Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative, was published by ACS Infectious Diseases on 15 July 2021.
Sameer Kumar Malladi et al, Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative, ACS Infectious Diseases (2021). DOI: 10.1021/acsinfecdis.1c00276
Study shows new ‘warm vaccine’ effective against all key virus variants (2021, July 15)
retrieved 15 July 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.